These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 10573104)

  • 1. Postoperative chemo-endocrine treatment with mitomycin C, tamoxifen, and UFT is effective for patients with premenopausal estrogen receptor-positive stage II breast cancer. Nishinihon Cooperative Study Group of Adjuvant Therapy for Breast Cancer.
    Sugimachi K; Maehara Y; Akazawa K; Nomura Y; Eida K; Ogawa M; Konaga E; Tanaka N; Toge T; Dohi K; Noda S; Maeda M; Monden Y
    Breast Cancer Res Treat; 1999 Jul; 56(2):113-24. PubMed ID: 10573104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan.
    Morimoto T; Ogawa M; Orita K; Sugimachi K; Toge T; Dohi K; Nomura Y; Monden Y; Ogawa N
    Eur J Cancer; 1996 Feb; 32A(2):235-42. PubMed ID: 8664034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy.
    Toi M; Ikeda T; Akiyama F; Kurosumi M; Tsuda H; Sakamoto G; Abe O
    Int J Oncol; 2007 Oct; 31(4):899-906. PubMed ID: 17786323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UFT and mitomycin plus tamoxifen for stage II, ER-positive breast cancer. Hokkaido ACETBC Study Group.
    Hata Y; Uchino J; Asaishi K; Kubo Y; Mito M; Tanabe T; Ogita M; Hirata K
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):91-5. PubMed ID: 10442372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status.
    Nomura Y; Shirouzu M; Takayama T
    Breast Cancer Res Treat; 1998 May; 49(1):51-60. PubMed ID: 9694611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of UFT plus Tamoxifen for Estrogen-Receptor-Positive Breast Cancer and Tamoxifen plus UFT for Estrogen-Receptor-Negative Breast Cancer : Adjuvant Therapy after Administration of Mitomycin.
    Ogita M; Uchino J; Asaishi K; Kubo Y; Tanabe T; Hata A; Hirata K; Mito M;
    Clin Drug Investig; 2003; 23(11):689-99. PubMed ID: 17536882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer stratified by estrogen receptors.
    Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
    Cancer; 1988 Jun; 61(11):2168-75. PubMed ID: 3130175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study.
    Park Y; Okamura K; Mitsuyama S; Saito T; Koh J; Kyono S; Higaki K; Ogita M; Asaga T; Inaji H; Komichi H; Kohno N; Yamazaki K; Tanaka F; Ito T; Nishikawa H; Osaki A; Koyama H; Suzuki T
    Br J Cancer; 2009 Aug; 101(4):598-604. PubMed ID: 19638976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of adjuvant tamoxifen to cyclophosphamide, methotrexate and 5-fluorouracil for premenopausal women with oestrogen receptor-positive breast cancer.
    Li HC; Wen XF; Hou YF; Shen KW; Wu J; Lu JS; Shen ZZ; Shao ZM
    Asian J Surg; 2003 Jul; 26(3):163-8. PubMed ID: 12925292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
    Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
    J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
    Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
    J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of five studies on tegafur plus uracil (UFT) as post-operative adjuvant chemotherapy for breast cancer.
    Kasumi F; Yoshimoto M; Uchino J; Abe R; Nomura Y; Sugimachi K; Nakazato H; Abe O
    Oncology; 2003; 64(2):146-53. PubMed ID: 12566912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection].
    Sadahiro S; Mitomi T; Noto T; Kumada K; Hiki Y; Yamakawa T; Amano T; Oki S; Otani Y; Oka H; Takahashi T; Takemiya S; Nishiyama K; Yamamura T; Tsuchiya S; Ogawa N;
    Gan To Kagaku Ryoho; 2005 Jul; 32(7):997-1005. PubMed ID: 16044962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
    Uchino J; Samejima N; Tanabe T; Hayasaka H; Mito M; Hata Y; Asaishi K
    Br J Cancer; 1994 Apr; 69(4):767-71. PubMed ID: 8142265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UFT in combination as adjuvant therapy for breast cancer. Grupo Oncologico de Sevilla Seville, Spain.
    Iglesias L; Moreno JA; Torrija E; Murillo E; Codes M; Dugue A; Garcia E; Virizuela JA
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):74-81. PubMed ID: 9348574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative adjuvant chemotherapy with mitomycin C and UFT for rectal cancer.
    Kodaira S
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):40-3. PubMed ID: 9348566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization.
    Toi M; Hattori T; Akagi M; Inokuchi K; Orita K; Sugimachi K; Dohi K; Nomura Y; Monden Y; Hamada Y
    Cancer; 1992 Nov; 70(10):2475-83. PubMed ID: 1423177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A randomized study of adjuvant treatments for operable breast cancer patients stratified by estrogen receptor and menopausal status].
    Nomura Y; Tsutsui S; Murakami S; Takenaka Y
    Gan To Kagaku Ryoho; 1999 Apr; 26(5):643-9. PubMed ID: 10234295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A comparative study among ftorafur, ftorafur plus tamoxifen, and tamoxifen in adjuvant therapy for breast cancer. The Chubu Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan].
    Yoshida M; Saji S; Takagi H; Takeuchi S; Tsuda H; Nimura Y; Mizumoto R; Miyazaki I; Kobayashi S; Noguchi M
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2325-33. PubMed ID: 8259846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.